{
  "parties": [
    "the parties.   1. Good Will. SCIEN recognizes that there exists great value",
    "good will associated with the Intellectual Property of Interferon alfa-n3 (human leukocyte derived)\"   2"
  ],
  "effective_date": null,
  "governing_law": null,
  "payment_terms": null,
  "termination_clause": {
    "text": "termination or expiration of this Agreement.   \"List Price\" means ${***}/Product Unit.   \"Product\" means an injectable formulation of clinical grade Interferon alfa-n3 (human leukocyte derived).\n\n{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.   Page 1 of 28\n\n\n\n\n\n\n\n  \"Product Data\" means all data possessed by HEMISPHERX relating to the use of Interferon alfa-n3 (human leukocyte derived) to treat patients in the Field and which is needed to obtain regulatory approval in the Territory.   \"Product Unit\" means 1 x1ml vial containing 5 million international units (I.U.) of Interferon alfa-n3 (human leukocyte derived)   \"Sales",
    "start": 3144,
    "end": 3955,
    "confidence": 0.72,
    "source": "regex"
  },
  "_doc_id": "HEMISPHERX - Sales, Marketing, Distribution, and Supply Agreement.txt",
  "_char_count": 73685,
  "_provenance": {}
}